Study Shows Presence of Cocaine-Like Substance in E-cigarettes in Brazil

Aug.16.2024
Study Shows Presence of Cocaine-Like Substance in E-cigarettes in Brazil
Preliminary research by UFSC and SC police reveals e-cigarettes in Brazil contain dangerous substances similar to methamphetamine.

According to a recent report by Brazilian media outlet Band.uol, a preliminary study conducted by the Federal University of Santa Catarina in collaboration with the state scientific police revealed the presence of a substance similar to amphetamines - octodrine, in e-cigarettes.


According to information released by Santa Catarina Federal University, traces of cocaine were found in three different brands of e-cigarettes collected from ten different samples in the northern city of Joinville in that state. The records also show that these samples contain ingredients such as glycerin, flavorings, and nicotine.


The study also found that the presence of synthetic drugs in the samples may lead to serious poisoning, dependence, withdrawal symptoms, and adverse cardiovascular effects similar to those of synthetic drugs such as methamphetamine acting on the central nervous system.


However, the Santa Catarina State Public Safety Department stated that the presence of cocaine was not indicated on the package label for sale.


The study also emphasizes that exposure of spices to high temperatures may generate harmful substances, particularly more evident with long-term use.


Furthermore, the research also indicates that e-cigarette users have nicotine levels three to six times higher than traditional cigarette smokers.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

 NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
According to The New York Times, Reynolds American donated $5 million to a Trump-backed super PAC shortly before the FDA introduced a new policy that could benefit major tobacco companies seeking to sell flavored vaping products.
News
May.21
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
From May 8 to 10, 2026, Mylor (Booth E70) will exhibit at The Vaper Expo UK, where it will showcase its systematic experience design solutions for e-liquids. At present, the e-liquid market commonly faces a challenge: many products have “no obvious shortcomings, but lack memorable features.” In response, Mylor has proposed refined solutions across multiple dimensions, including device-adaptive sweetness, progressive cooling sensation, fruit-oriented sourness, and segmented nicotine experience.
May.08
Bangladesh Industry Association Calls for Regulated Framework Instead of Vape Ban
Bangladesh Industry Association Calls for Regulated Framework Instead of Vape Ban
Bangladesh Electronic Nicotine Delivery Systems Traders Association said at a press conference on April 9 that use of e-cigarette products under regulated policy frameworks has produced positive public health outcomes globally.
Apr.10 by 2FIRSTS.ai
Exclusive | Shenzhen Tobacco Authorities Ask Licensed Chinese Vape Manufacturers to Submit STN Details for U.S.-Bound Products
Exclusive | Shenzhen Tobacco Authorities Ask Licensed Chinese Vape Manufacturers to Submit STN Details for U.S.-Bound Products
Shenzhen tobacco authorities have asked licensed Chinese vape manufacturers to submit STN details for U.S.-bound products, including CTP Portal or STN email screenshots, highlighting a new compliance signal in cross-border oversight.
Apr.02
AIR Romania Manufacturing Facility Expected to Begin Operations in Q1 2027
AIR Romania Manufacturing Facility Expected to Begin Operations in Q1 2027
AIR Limited announced on May 7, 2026, that it plans to open a new manufacturing facility of approximately 70,000 square feet in Stefanesti, Bucharest North, Romania. The facility is expected to begin operations by the first quarter of 2027. AIR said that once fully operational, the facility is expected to support more than 150 jobs and be capable of producing more than 4,000 tons of flavored shisha molasses each year.
May.08 by 2FIRSTS.ai
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai